US Pharma MarketingThe post Protara’s cell therapy shows treatment durability in mid-stage NMIBC study appeared first on Clinical Trials Arena.
Protara’s cell therapy shows treatment durability in mid-stage NMIBC study
If Protara secures approval for TARA-002 in NMIBC, it would become the first drug in its class to get the regulatory greenlight. If approved, TARA-002 could become the first cell therapy to get the regulatory go-ahead in NMIBC and the first drug indicated for BCG-naïve patients. Protara is looking to conduct a registrational NMIBC study on TARA-002 in H2 2026. Credit: mi_viri / Shutterstock.com. Protara Therapeutics’ solid tumour-focused cell therapy, TARA-002, has demonstrated its potential to elicit a durable response in patients with non-muscle invasive bladder cancer (NMIBC) during a Phase II trial. The open-label ADVANCED-2 study (NCT05951179) enrolled 31…
If Protara secures approval for TARA-002 in NMIBC, it would become the first drug in its class to get the regulatory greenlight.
Source: Clinical Trials Arena